Patrick J. Haley Sells 10,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total value of $352,700.00. Following the completion of the transaction, the executive vice president now directly owns 278,665 shares in the company, valued at approximately $9,828,514.55. This trade represents a 3.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Stock Up 0.2 %

EXEL stock opened at $36.45 on Wednesday. The stock has a market capitalization of $10.41 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.51. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.72. The firm has a 50 day moving average of $30.08 and a 200 day moving average of $25.73.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same period in the previous year, the firm posted $0.10 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, equities research analysts expect that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Institutional Trading of Exelixis

Several large investors have recently added to or reduced their stakes in EXEL. Farallon Capital Management LLC raised its stake in shares of Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Exelixis by 0.4% during the 2nd quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after acquiring an additional 61,350 shares during the period. LSV Asset Management boosted its holdings in shares of Exelixis by 107.7% in the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after acquiring an additional 2,989,021 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after acquiring an additional 349,837 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Exelixis by 12.7% during the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after purchasing an additional 370,199 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. JMP Securities reiterated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. UBS Group assumed coverage on shares of Exelixis in a research note on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 target price on shares of Exelixis in a report on Wednesday, October 30th. Bank of America boosted their price target on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Wells Fargo & Company increased their price objective on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.